Trial Profile
A pilot study of a myeloablative regimen with a reduced cyclophosphamide dose, adjunctive serotherapy and matched unrelated donors hematopoietic stem cell transplantation in patients with non-malignant genetic diseases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Feb 2016
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Busulfan (Primary) ; Ciclosporin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Methylprednisolone (Primary) ; Tacrolimus (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 11 Feb 2016 New trial record